

Orchard Therapeutics, SIRION Biotech partners for gene therapy

18 December 2018 | News

Under the terms of the agreement, SIRION will provide Orchard with a license to its proprietary lentiviral transduction enhancer LentiBOOST™ for development and commercialization activities for select Orchard programs



Orchard Therapeutics, a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.

The company has announced the entry into a license agreement with SIRION Biotech GmbH, pursuant to which Orchard has licensed SIRION's LentiBOOST™ technology to enhance manufacturing efficiency for certain of Orchard's *sex vivo* autologous hematopoietic stem cell gene therapy drug candidates.

Under the terms of the agreement, SIRION will provide Orchard with a license to its proprietary lentiviral transduction enhancer LentiBOOST™ for development and commercialization activities for select Orchard programs. SIRION will be entitled to upfront and milestone payments and is eligible to receive royalties on net sales of future products that utilize the LentiBOOST™ technology.